Related Experiment Videos

[New hormones and cytostatic drugs in tumor therapy]

D Lüftner¹, K Possinger

¹Medizinische Klinik und Poliklinik II, Universitätsklinikum Charité, Humboldt-Universität Berlin.

|February 7, 1998

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study.

ESMO open·2025

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Patients' perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life-a study of the North-Eastern-German Society of Gynecological Oncology.

Archives of gynecology and obstetrics·2019

Energy Ordering of Molecular Orbitals.

The journal of physical chemistry letters·2016

ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07. 11. 2015.

Geburtshilfe und Frauenheilkunde·2016

Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries.

Journal of bone oncology·2016

See all related articles